Core Viewpoint - Shanghai Haixin Group Co., Ltd. has successfully completed the transfer of 51.3249% equity in Shanghai Haixin Pharmaceutical Co., Ltd. to Chongqing Huisheng Yunjian Business Information Consulting Center for a total consideration of 23.0494 million yuan [2][3]. Group 1: Transaction Overview - The board of directors approved the equity transfer on September 25, 2023, and authorized the management to handle the transaction [3]. - The total transaction price for the equity transfer was set at 23.0494 million yuan [3]. - As of the announcement date, Haixin Asset has received a total of 21.8969 million yuan from Huisheng Yunjian, which accounts for 95% of the agreed transfer price [3]. Group 2: Payment Progress - The third payment of 1.1525 million yuan was recently received, completing the total payment for the equity transfer [4]. - The total amount received from Huisheng Yunjian for the equity transfer is now 23.0494 million yuan, marking the full recovery of the transfer price [4].

证券代码：600851 证券简称：海欣股份 公告编号：2025-017 900917 海欣B股 上海海欣集团股份有限公司关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025年6月18日 14点00分 召开地点：上海市松江区洞泾镇长兴路688号海欣集团3楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025年6月18日 至2025年6月18日 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融 ...

前十大流通股东累计持有： 50820.45万股，累计占流通股比： 42.1%，较上期变化： -0.50万股。 | 名称 | 持有数量(万股) | 占总股本 | 增减情况 | | --- | --- | --- | --- | | | | 比例(%) | (万股) | | 1、湖南凝瑞投资合伙企业(有限合伙) | 14152.88 | 11.73 | 新进 | | 2、上海松江洞泾工业公司 | 8208.20 | 6.80 | 新进 | | 3、宁波梅山保税港区鑫芯私募基金管理合伙企业(有限合伙)- | 6000.00 | 4.97 | 新进 | | 嘉兴青芯正茂股权投资合伙企业(有限合伙) | | | | | 4、上海玩具进出口有限公司 | 3930.00 | 3.26 | 新进 | | 5、湖南财信经济投资有限公司 | 3928.82 | 3.25 | 新进 | | 6、重庆国际信托股份有限公司 | 3339.07 | 2.77 | 新进 | | 7、GUOTAI JUNAN SECURITIES(HONGKONG)LIMITED | 3160.47 | 2.62 | 新进 | | 8、申海有限公司 | 2 ...

证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2024-024 上海海欣集团股份有限公司 关于参加上海辖区上市公司 2024 年投资者 网上集体接待日暨中报业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可提前通过公司邮箱 600851@haixin.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 上海海欣集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 24 日发布公 司 2024 年半年度报告。为进一步加强与投资者的互动交流，公司将参加由上海上市 公司协会与深圳市全景网络有限公司联合举办的"2024 年上海辖区上市公司投资者集 体接待日暨中报业绩说明会"，现将相关事项公告如下： 一、 说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2024 年半年度的经营成果及 财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资 者普遍关注的问题进行回答。 1 会议召开时间：2024 年 9 月 ...

2024 年半年度报告 公司代码：600851 公司简称：海欣股份 900917 海欣 B 股 上海海欣集团股份有限公司 2024 年半年度报告 1 / 150 2024 年半年度报告 重要提示 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的公司有关未来发展战略和经营计划等前瞻性内容，不构成公司对投资者的实 质承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中描述可能存在的相关风险，敬请查阅"第三节管理层讨论与分析"中"其 他披露事项"中"可能面对风险"的内容。 十一、 其他 □适用 √不适用 2 / 150 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人费敏华、主管会计工作负责人 ...

Financial Performance - The company's operating revenue for the year 2023 reached CNY 4,988,253.83, an increase from CNY 3,355,622.30 in 2022, representing a growth of approximately 48.6%[31] - The net profit for 2023 was CNY 99,119,499.26, compared to CNY 166,240,576.08 in 2022, indicating a decrease of about 40.3%[31] - Basic earnings per share for 2023 were CNY 0.1376, slightly up from CNY 0.1359 in 2022[30] - The company reported investment income of CNY 162,678,613.50 for 2023, down from CNY 214,660,127.20 in 2022, a decline of approximately 24.2%[31] - The total operating profit for 2023 was CNY 94,911,546.44, a decrease from CNY 157,671,625.00 in the previous year, reflecting a decline of about 39.8%[31] - The total profit amounted to ¥207,181,178.48, a decrease from ¥230,329,731.65 in the previous period, reflecting a decline of approximately 10%[34] - Net profit for the period was ¥192,107,136.51, compared to ¥198,382,453.82 in the prior year, indicating a decrease of about 3%[34] - The net profit attributable to shareholders of the parent company was ¥166,030,649.74, slightly up from ¥164,056,061.10, showing an increase of approximately 1.2%[34] - The total comprehensive income for the period was ¥202,115,102.45, contrasting with a loss of ¥206,921,483.57 in the previous period[34] - The total comprehensive income for the year was 176.04 million yuan, with a net profit distribution of -64.23 million yuan[70] Cash Flow and Assets - The cash flow from operating activities was 1,214.46 million yuan, down from 1,547.99 million yuan in the previous year[65] - Cash and cash equivalents increased to ¥509.55 million from ¥420.29 million, representing a growth of approximately 21% year-over-year[174] - Total current assets decreased from 1,087,716,787.09 to 993,987,824.74, a decline of approximately 8.6%[178] - Long-term equity investments increased from 1,127,034,374.09 to 1,181,061,183.99, representing a growth of about 4.8%[178] - Total liabilities decreased from 911,215,769.39 to 775,286,878.90, a reduction of approximately 14.9%[180] - Total owner's equity increased from 4,018,848,320.64 to 4,135,338,280.38, reflecting an increase of about 2.9%[180] - Cash and cash equivalents rose from 228,011,028.77 to 290,632,320.87, an increase of approximately 27.5%[186] - Total assets decreased slightly from 4,930,064,090.03 to 4,910,625,159.28, a decrease of about 0.4%[180] Expenses and Costs - Total operating costs for 2023 were $1,116,082,358.77, down about 21.3% from $1,416,807,804.41 in 2022[190] - Operating profit for 2023 was $210,512,398.60, a decline of around 8.4% from $229,889,547.81 in 2022[190] - Research and development expenses increased to $23,109,998.20 in 2023, compared to $22,672,328.29 in 2022, reflecting a growth of approximately 1.9%[190] - Sales expenses decreased to $327,042,249.54 in 2023, a reduction of about 25% from $434,867,383.46 in 2022[190] - Management expenses were $123,438,537.06 in 2023, down from $145,232,641.24 in 2022, indicating a decrease of approximately 15%[190] - Tax expenses for 2023 were $17,989,872.04, significantly lower than $44,298,106.17 in 2022, marking a decrease of about 59.5%[190] - Other income for 2023 was $2,838,674.31, down from $6,669,192.60 in 2022, reflecting a decline of approximately 57.5%[190] - Financial expenses showed a net income of -$7,073,168.60 in 2023, compared to -$5,437,487.47 in 2022, indicating an increase in financial costs[190] Shareholder Information - The proposed cash dividend is ¥0.65 per 10 shares, totaling ¥78,458,684.98, which is 47.26% of the net profit attributable to shareholders[56] - There were no significant changes in the shareholding structure during the reporting period, with the largest shareholder holding 11.73% of the shares[20] - The company reported no guarantees provided to external parties, while guarantees to subsidiaries totaled ¥1,375.00, representing 0.35% of the company's net assets[35] - The company has not incurred any new guarantees during the reporting period, maintaining a stable financial position[35] Strategic Initiatives - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[34] - The company is focusing on enhancing its corporate culture and party building to boost team spirit and business development[60] - The company is committed to improving risk prevention effectiveness through optimized internal control systems[60] - The company emphasizes the importance of innovation in technology, products, and market strategies to remain competitive in the increasingly challenging pharmaceutical industry[98] - The company is actively engaged in research and development to enhance product quality and efficacy, driven by government policies supporting pharmaceutical innovation[98] - The company has a commitment to expanding its market presence and exploring new investment opportunities in line with national industrial policies[74] - Future outlook includes plans for market expansion and potential acquisitions to enhance growth opportunities[151] - The company is exploring strategic partnerships to leverage synergies and enhance market presence[151] Compliance and Governance - The company has strengthened its internal management mechanisms and governance levels in compliance with legal regulations[60] - The financial report was approved for publication on April 18, 2024, indicating the company's adherence to regulatory requirements[74] - The company has maintained its accounting policies consistent with the previous year, ensuring comparability in financial reporting[110] - The financial statements have been prepared in accordance with applicable accounting standards, ensuring transparency and accuracy[110]

Financial Performance - Q3 2023 revenue was CNY 321,539,166.53, a decrease of 22.03% year-over-year[3] - Net profit attributable to shareholders was CNY 24,262,874.13, down 46.13% compared to the same period last year[3] - Basic earnings per share decreased by 46.11% to CNY 0.0201[4] - Total operating revenue for the first three quarters of 2023 was CNY 946,698,652.49, a decrease of 9.8% compared to CNY 1,048,902,061.80 in the same period of 2022[17] - Net profit for the first three quarters of 2023 was CNY 131,618,732.09, a decline of 27.6% from CNY 181,714,625.37 in 2022[18] - Earnings per share for the third quarter were CNY 0.1043, down from CNY 0.1410 in the previous year[19] Assets and Liabilities - Total assets increased by 2.90% to CNY 5,072,793,296.77 compared to the end of the previous year[4] - As of September 30, 2023, the total assets of the company amounted to CNY 5,072,793,296.77, an increase from CNY 4,930,064,090.03 at the end of 2022, representing a growth of approximately 2.88%[13] - The total liabilities decreased slightly to CNY 911,120,500.25 from CNY 911,215,769.39, indicating a marginal reduction of approximately 0.01%[15] - The total current liabilities decreased to CNY 441,054,176.94 from CNY 472,471,150.87, showing a decline of approximately 6.64%[15] - The company's total equity attributable to shareholders increased to CNY 4,011,605,322.87 from CNY 3,843,579,153.36, representing a growth of 4.4%[16] Cash Flow - Cash flow from operating activities was CNY 31,746,564.80, an increase of 7.21% year-over-year[3] - Operating cash flow for the first nine months of 2023 was CNY 35,474,802.50, a decrease from CNY 40,002,254.43 in the same period of 2022, reflecting a decline of approximately 3.3%[24] - Total cash inflow from operating activities was CNY 1,024,531,608.07, compared to CNY 1,154,783,645.74 in the previous year, indicating a decrease of about 11.2%[24] - Cash inflow from investment activities increased to CNY 864,504,202.52 from CNY 737,641,448.98, representing a growth of approximately 17.2%[25] - Net cash flow from investment activities was CNY 146,844,967.83, up from CNY 82,160,513.41, showing an increase of about 78.8%[25] - Cash inflow from financing activities totaled CNY 71,079,404.26, compared to CNY 64,679,105.50, marking an increase of approximately 9.3%[25] - Net cash flow from financing activities was negative at CNY -52,562,278.08, worsening from CNY -44,648,448.62 in the previous year[25] - The ending balance of cash and cash equivalents was CNY 551,312,552.69, up from CNY 404,489,751.26, reflecting an increase of about 36.3%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 64,114[9] - The top shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 11.73% of the shares[9] Operational Insights - The company plans to focus on improving operational efficiency and exploring new market opportunities[7] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] Other Financial Metrics - The company reported a decrease in investment income from associates, contributing to the decline in net profit[7] - Investment income for the first three quarters was CNY 115,566,685.23, down from CNY 175,179,431.91, indicating a decrease of 34.0%[18] - Other comprehensive income after tax for the third quarter was CNY 94,646,632.77, a significant recovery from a loss of CNY 429,659,513.94 in the previous year[18] - The company reported a decrease in sales expenses to CNY 288,897,754.42 from CNY 372,198,510.68, a reduction of 22.5%[17] - Management expenses decreased to CNY 88,434,728.03 from CNY 100,047,385.68, reflecting a decline of 11.6%[17] - The company's accounts receivable decreased to CNY 149,941,986.02 from CNY 174,382,888.61, a reduction of about 13.96%[13] - The company's inventory decreased to CNY 79,049,664.55 from CNY 89,520,866.14, reflecting a decline of approximately 11.7%[14] - The company reported a significant increase in other receivables, rising to CNY 43,795,581.05 from CNY 35,091,523.76, an increase of approximately 24.5%[14] - Total cash outflow from investment activities was CNY 717,659,234.69, compared to CNY 655,480,935.57, representing an increase of about 9.5%[25] - Cash received from the recovery of investments was CNY 787,638,163.43, compared to CNY 625,083,307.80, indicating an increase of approximately 26%[24] - Cash received from other operating activities was CNY 61,963,637.42, significantly higher than CNY 35,306,486.61, showing an increase of approximately 75.9%[24] - Non-recurring gains and losses totaled CNY -1,508,906.34 for the current period[6]

证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2023-021 上海海欣集团股份有限公司 关于参加上海辖区上市公司 2023 年投资者 网上集体接待日活动暨中报业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 会议召开时间：2023 年 9 月 7 日 14:00-16:30 会议召开地点："全景路演"网站（网址 http://rs.p5w.net） 会议召开方式：网络互动交流 投资者可在本次活动召开前，扫描本公告中的二维码，提前留言提问。公司将在 业绩说明会期间对投资者普遍关注的问题进行回答。 上海海欣集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 26 日披露公 司 2023 年半年度报告。为进一步加强与投资者的互动交流，公司将参加由上海证监 局、上海上市公司协会与深圳市全景网络有限公司联合举办的 2023 年上海辖区上市 公司集体接待日活动暨中报业绩说明会，就投资者关心的问题进行交流。 1 一、说明会类型 本次说明会将以网络互动形式召开，公司将针对 2023 年半年度经营 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥282,592,919.46, representing a decrease of 6.66% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥26,525,288.95, down by 2.89% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 10.15% to ¥26,273,745.64[5]. - The net profit for Q1 2023 was CNY 27,014,690.72, a decrease of 7.5% compared to CNY 29,259,143.67 in Q1 2022[19]. - Operating profit for Q1 2023 was CNY 29,209,428.18, down from CNY 32,609,582.98 in the same period last year, reflecting a decline of 7.3%[19]. - The total comprehensive income for Q1 2023 was CNY 70,536,351.32, compared to a loss of CNY 215,686,395.08 in Q1 2022[20]. - The total revenue from sales of goods and services in Q1 2023 was CNY 294,546,469.52, a decrease of 15.2% from CNY 347,428,782.83 in Q1 2022[21]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥3,828,556.17, a decline of 120.05% compared to the previous year[5]. - Cash flow from operating activities showed a net outflow of CNY 3,828,556.17 in Q1 2023, compared to a net inflow of CNY 19,097,360.28 in Q1 2022[22]. - Cash flow from investing activities resulted in a net outflow of CNY 9,366,748.98 in Q1 2023, a significant decrease from a net inflow of CNY 48,276,678.66 in Q1 2022[22]. - The company's cash and cash equivalents as of March 31, 2023, were CNY 418,431,222.38, slightly down from CNY 420,285,866.49 at the end of 2022[15]. - The cash and cash equivalents at the end of Q1 2023 stood at CNY 418,431,222.38, compared to CNY 395,419,292.24 at the end of Q1 2022, reflecting an increase of 5.3%[23]. - Total assets at the end of the reporting period were ¥4,984,250,435.15, an increase of 1.10% from the end of the previous year[6]. - The total assets increased to CNY 4,984,250,435.15 from CNY 4,930,064,090.03, representing a growth of 1.1%[18]. - Total liabilities decreased to CNY 894,865,763.19 from CNY 911,215,769.39, a reduction of approximately 1.8%[17]. Shareholder Information - Basic and diluted earnings per share were both ¥0.0220, down by 2.65%[6]. - The total number of ordinary shareholders at the end of the reporting period was 68,059, with 36,051 A-shareholders and 32,008 B-shareholders[11]. - The company reported a basic and diluted earnings per share of CNY 0.0220 for Q1 2023, slightly down from CNY 0.0226 in Q1 2022[20]. Costs and Expenses - Total operating costs for Q1 2023 were CNY 274,024,708.30, down 7.6% from CNY 296,583,327.39 in Q1 2022[18]. - Research and development expenses for Q1 2023 were CNY 4,221,568.55, down from CNY 4,743,720.99 in Q1 2022, indicating a decrease of about 11%[18]. - The company incurred a tax expense of CNY 2,302,342.80 in Q1 2023, down from CNY 3,080,536.61 in Q1 2022, indicating a reduction of 25.3%[19]. - The significant decrease in cash flow was primarily due to increased tax payments, including ¥30.83 million in VAT and ¥9.72 million in land value-added tax[9]. Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥251,543.31 for the period[8]. - The company reported an investment income of CNY 20,949,413.12 for Q1 2023, compared to CNY 22,970,174.34 in Q1 2022, reflecting a decline of approximately 8.8%[18]. - The company reported a significant increase in other comprehensive income, amounting to CNY 43,521,660.60 in Q1 2023, compared to a loss of CNY 244,945,538.75 in Q1 2022[19]. Accounts Receivable and Inventory - Accounts receivable decreased to CNY 147,053,109.62 from CNY 174,382,888.61, reflecting a reduction of approximately 15.7%[15]. - Inventory as of March 31, 2023, was CNY 87,473,441.31, a slight decrease from CNY 89,520,866.14 at the end of 2022[16].

Financial Performance - In 2022, the company achieved a net profit attributable to shareholders of RMB 164,056,061.10, representing a 24.20% increase compared to RMB 132,091,780.53 in 2021[6]. - The company's operating revenue for 2022 was RMB 1,440,090,739.79, a decrease of 4.71% from RMB 1,511,255,284.73 in 2021[23]. - The net cash flow from operating activities decreased by 66.51% to RMB 73,558,233.78, down from RMB 219,647,104.26 in the previous year[23]. - The basic earnings per share for 2022 increased by 24.22% to RMB 0.1359, compared to RMB 0.1094 in 2021[25]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which rose by 50.03% to RMB 155,822,289.93[23]. - The company achieved a consolidated revenue of CNY 1.44 billion in 2022, a decrease of 4.71% year-on-year[45]. - The net profit attributable to the parent company was CNY 164 million, an increase of 24.20% year-on-year[45]. - Total revenue for the year was approximately CNY 1,277.75 million, a decrease of 5.92% compared to the previous year[50]. Asset Management - The company's total assets as of the end of 2022 were RMB 4,930,064,090.03, a decrease of 7.43% from RMB 5,325,619,470.52 at the end of 2021[23]. - The company’s net assets attributable to shareholders decreased by 6.90% to RMB 3,843,579,153.36 at the end of 2022, down from RMB 4,128,288,109.68 at the end of 2021[23]. - The total assets at the end of 2022 were CNY 4.93 billion, a decrease of 7.43% primarily due to a decline in the market value of holdings in Changjiang Securities[45]. - The company disposed of inefficient assets to improve overall asset quality, establishing a dedicated asset disposal task force[39]. - The company’s long-term equity investments increased to RMB 1,127.03 million in 2022, compared to RMB 1,080.90 million in 2021, marking an increase of about 4.3%[194]. Segment Performance - The pharmaceutical segment reported a consolidated operating revenue of 801.98 million RMB, down 8.13% year-on-year, with a net profit of 19.09 million RMB, up 35.12%[33]. - The property segment generated rental income of 75.43 million RMB, an increase of 5.32% year-on-year, and operating net profit of 49.11 million RMB, up 21.32%[35]. - The textile segment reported operating revenue of 231.94 million RMB, an increase of 13.31% year-on-year, but incurred a net loss of 9.03 million RMB due to restructuring costs[36]. - The company reported a net cash flow from operating activities of 33.56 million RMB in Q4 2022, indicating improved cash generation capabilities[27]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 0.45 per 10 shares, totaling RMB 54,317,551.14, which accounts for 33.11% of the net profit attributable to shareholders[6]. - The cash dividend per 10 shares is CNY 0.45, with no stock dividends or capital increases proposed[123]. - The company declared a cash dividend of CNY 54,317,551.14, which represents 33.11% of the net profit attributable to ordinary shareholders in the consolidated financial statements[123]. Risk Management - The company highlighted risks related to future development strategies and operational plans, advising investors to be cautious[9]. - The company faces market risks due to intense competition in its pharmaceutical and textile businesses, which could significantly impact performance[77]. - Regulatory risks from stricter environmental policies and changes in healthcare and real estate regulations may affect the company's operations[78]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, complying with legal requirements[85]. - The supervisory board is composed of 2 supervisors and 1 employee supervisor, adhering to legal standards[86]. - The company has established a performance evaluation and incentive mechanism linking senior management compensation to company and individual performance[87]. - The company has implemented an information disclosure management system to ensure timely and accurate information dissemination to shareholders[88]. Environmental Compliance - The company has implemented effective measures to ensure that all emissions are within the regulatory limits, demonstrating commitment to environmental compliance[135]. - The company has a wastewater treatment station with a daily capacity of 1,500 tons, which discharges treated water to an industrial wastewater treatment plant for further processing before discharge[140]. - The company reported no administrative penalties for environmental issues during the reporting period[144]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[96]. - The company is investing in R&D for new technologies, with an allocated budget of $50 million for the upcoming year[96]. - Market expansion plans include entering three new international markets by the end of 2024, aiming for a 10% market share in each[96].